(346) Nano-in-micro particles for the pulmonary delivery of remdesivir
Introduction: Remdesivir (RDV) emerged as a potential therapeutic option to treat COVID-19 in patients with comorbidities [1,2]. Due to its low oral bioavailability, RDV must be administered intravenously (2h infusion), and the rapid metabolism during systemic circulation may further limit its therapeutic efficacy in the lungs, since the active metabolite is unable to penetrate cell membranes [3]. Here we developed an inhalable formulation of nanoparticles (NPs) incorporated into microparticles (MPs) for pulmonary delivery of RDV.
Learning Objectives:
Nanoencapsulation of remdesivir resulted in stable and high load nanoparticles;
The nano-in-microparticles present adequate size to deliver remdesivir to the lungs;
The formulation developed is promising to incorporate other drugs to treat pulmonary diseases.
Alison Tatiana Sani – PhD., School of Pharmaceutical Sciences, University of São Paulo; Brenno Lima – Student, School of Medicine, Federal University of São Paulo; Beatriz Rodrigues – Student, School of Medicine, Federal University of São Paulo; Michelle Sarcinelli – Researcher, Oswaldo Cruz Foundation; Marcelo Henrique Chaves – Researcher, Oswaldo Cruz Foundation; Helvécio Vinícius Rocha – Researcher, Oswaldo Cruz Foundation; Natalia Cerize – Director of Strategy and International Relations, Bionanomanufacturing Center, Tchnological Research Institute; Maria Helena Zanin – Researcher, Bionanomanufacturing Center, Technological Research Center; Juliana Maricato – Professor, School of Medicine, Federal University of São Paulo; Valker Feitosa – Preofessor, School of Pharmaceutical Sciences, University of São Paulo
